Business Context and Reporting Period
This Form 8-K reports on the 2020 Annual Meeting of Stockholders for Alnylam Pharmaceuticals, Inc., held on May 6, 2020. The report details the voting outcomes for director elections, plan amendments, executive compensation, and auditor ratification.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes are reported in this document. The primary events are the successful re-election of directors and the approval of stock plan amendments and executive compensation.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks and contingencies. It strictly reports the results of shareholder votes.
Key Facts for Investor Verification
- Shareholder Base: As of the March 9, 2020 record date, 113,072,381 shares of common stock were issued and outstanding.
- Director Elections: Stockholders re-elected Michael W. Bonney, John M. Maraganore, Ph.D., and Phillip A. Sharp, Ph.D. as Class I directors. All three received significant majority support, though Mr. Bonney received approximately 8.3% of votes against.
- Stock Plan Amendments: Stockholders approved amendments to both the 2018 Stock Incentive Plan and the 2004 Employee Stock Purchase Plan.
- Executive Compensation: The non-binding advisory vote on executive compensation was approved with approximately 94.0 million votes in favor versus 3.2 million against.
- Auditor Ratification: PricewaterhouseCoopers LLP was ratified as the independent auditor for the fiscal year ending December 31, 2020, with overwhelming support (101.3 million votes for).